Isolation and characterization of a bacteriophage phiEap-2 infecting multidrug resistant Enterobacter aerogenes

Erna Li1,2, Xiao Wei2, Yanyan Ma3,2

  • 1College of Food Science, South China Agricultural University, Guangzhou, 510642, China.

Scientific Reports
|June 21, 2016
PubMed

Insights

Bacteriophage phiEap-2 can lyse multidrug-resistant Enterobacter aerogenes. Its genome sequencing provides insights for developing new antimicrobial therapies against this opportunistic pathogen.

Area of Science:

  • Microbiology
  • Genomics
  • Infectious Diseases

Background:

  • Enterobacter aerogenes is an opportunistic pathogen causing hospital-acquired infections.
  • Multidrug-resistant strains of E. aerogenes pose a significant public health challenge.
  • There is a need for novel antimicrobial strategies to combat resistant bacterial infections.

Purpose of the Study:

  • To isolate and characterize a bacteriophage with lytic activity against multidrug-resistant Enterobacter aerogenes.
  • To determine the complete genome sequence of the isolated bacteriophage phiEap-2.
  • To analyze the genomic features of phiEap-2 for potential therapeutic applications.

Main Methods:

  • Isolation of bacteriophage phiEap-2 from sewage.
  • Determination of the complete genome sequence of phiEap-2.
  • Morphological characterization using electron microscopy.
  • Comparative genomic analysis with related phages.

Main Results:

  • Phage phiEap-2 was isolated and shown to lyse a multidrug-resistant E. aerogenes strain.
  • Morphological analysis indicated phiEap-2 belongs to the Siphoviridae family.
  • The complete genome sequence of phiEap-2 was determined and analyzed.
  • phiEap-2 shares genomic similarities with Salmonella phage FSL SP-031 and Serratia phage Eta.

Conclusions:

  • The genome sequence of bacteriophage phiEap-2 provides valuable information for understanding its biology.
  • phiEap-2 represents a potential candidate for phage therapy against multidrug-resistant Enterobacter aerogenes infections.
  • Further research into phiEap-2 could lead to the development of novel antimicrobial agents.